Galmed Pharmaceuticals Ltd.
A clinical-stage drug development biopharmaceutical company for liver, metabolic & inflammatory diseases
A clinical-stage drug development biopharmaceutical company for liver, metabolic & inflammatory diseases
Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide. Our corporate headquarters is located in Tel Aviv, Israel. For more information about Galmed, please visit our website at: www.galmedpharma.com
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $7.00M | - | 14 Jul 2023 | |
| Post-IPO Equity | $10.00M | - | 16 Feb 2021 | |
| Post-IPO Equity | $75.00M | - | 21 Jun 2018 | |
| Post-IPO Equity | $11.60M | 2 | Meitav Investment House, Sphera Funds Management | 03 Jan 2018 |
No recent news or press coverage available for Galmed Pharmaceuticals Ltd..
We care about your data, and we'd love to use cookies make your experience better.
